Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...

A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, ...

The "Hepatitis B - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.This report outlays comprehensive insights of present clinical development scenario and ...

Functional cure of chronic hepatitis B (CHB) remains a major clinical challenge. Current therapies—including nucleos(t)ide ...

Patients attending Medway Maritime Hospital's A&E will now be routinely tested for HIV and hepatitis unless they opt out. The ...

Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of ...

The Knox County Health Department shared in a press release that each May, the United States observes Hepatitis Awareness Month to bring attention to viral hepatitis and ...